"Understanding the Molecular Pathogenesis of Phenotypes using Gene Co-Expression Network-Based Models."

Dr. James L. Stevens Eli Lilly & Co.

Date and Location

When (Date/Time)

November 8, 2017, 11:00 AM - 12:00 PM

Add to calendar


Dr. Stevens is a Distinguished Research Fellow at Lilly Research Laboratories. For over four decades in government, academics and industry he has studied molecular and cellular responses to the metabolism and toxicity of drugs and xenobiotics.  His current research focuses on application of systems biology approaches to improving drug safety assessment and elucidating mechanisms of drug toxicity.  Dr. Stevens received his Ph.D. in Pharmacology from the University of Minnesota in 1980.  Prior to joining Lilly Research Laboratory in 2000, he held positions at the National Institutes of Health, the Food and Drug Administration, the University of Vermont and the W. Alton Jones Cell Science Center, where he was Executive Director.  He has served on a variety of national advisory committees including the HESI Board of Trustees, National Advisory General Medical Sciences at NIH, National Toxicology Program Board of Scientific Councilors (BOSC), the EPA Board of Scientific Councilors, Subcommittee on Chemical Safety for Sustainability, as well as the Boards of Directors for Argonex Pharmaceuticals, Inc., and Upstate Biotechnology, Inc.  He received the Achievement Award from the Society of Toxicology in 1994 and was elected a Fellow of the American Association for the Advancement of Sciences in 1996. Dr. Stevens is recognized internationally as an expert in drug safety science and the application of systems biology approaches to drug-induces organ toxicity.  He has active collaborations in Europe and was instrumental in launching the Innovative Medicine Initiative 2 (IMI2) project titled, “Translational Quantitative Systems Toxicology” (TransQST) initiated in January of 2017 and leads participation for Lilly in the IMI1 “Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury” (MIPDILI) which wraps up activities in 2017.

Contact Information